Form 4: Vir Biotech CFO Sells Shares for Tax Obligations

Vir Biotechnology's EVP & CFO, Jason O'Byrne, sold 1,634 shares of common stock to cover tax withholding obligations from restricted stock unit vesting.

Summary

• Jason O'Byrne, Executive Vice President and Chief Financial Officer of Vir Biotechnology, Inc. (VIR), reported a transaction on February 24, 2026.
• The transaction involved the sale of 1,634 shares of Vir Biotechnology Common Stock at a price of $9.5326 per share.
• This sale was an automatic and mandatory transaction executed under a Rule 10b5-1 arrangement.
• The purpose of the sale was to satisfy the Issuer's tax withholding obligations in connection with the vesting of restricted stock units.
• The sale does not represent a discretionary trade by Mr. O'Byrne.
• Following this transaction, Mr. O'Byrne beneficially owns 162,615 shares of Common Stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. It reports a routine, non-discretionary insider transaction for tax purposes, which does not reflect a change in the company's fundamentals or management's outlook.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The sale represents an automatic and mandatory sale of shares under a Rule 10b5-1 arrangement to satisfy the Issuer's tax withholding obligations in connection with the vesting of restricted stock units.
• The sale does not represent a discretionary trade by the Reporting Person.

Industry Context

StockSavvy.ai notes that sales of shares by executives to cover tax withholding obligations upon the vesting of restricted stock units are a common and routine occurrence in the biotechnology industry and across publicly traded companies. These transactions are typically non-discretionary and pre-scheduled under Rule 10b5-1 plans, indicating no change in management's sentiment towards the company's prospects.

Stakeholder Impact

• Shareholders: Minimal impact, as this is a routine, non-discretionary sale for tax purposes and does not signal a change in the company's prospects or management's confidence.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary sale of shares by an executive to cover tax obligations associated with restricted stock unit vesting. Such transactions are common and pre-scheduled under Rule 10b5-1 plans, and do not provide new fundamental information about Vir Biotechnology's operational performance, strategic direction, or future prospects. Therefore, a seasoned investor or institution would likely maintain their current position, as this filing does not present a compelling reason to alter an existing investment thesis.

Keywords

Vir Biotechnology, VIR, Form 4, Insider Transaction, Stock Sale, Tax Withholding, Restricted Stock Units, Jason O'Byrne, CFO